ACON Aclarion, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACON Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Health Information Services
Current Price
Live
$2.58
Analyst Target
$23.0
+791.5%
Upside
52W High
$229.5
52W Low
$2.34
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$2.72M
P/E
N/A
ROE
-97.7%
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
95%
Analysis Accuracy
ACON's deterministic health scores are severely negative, with a Piotroski F-Score of 1/9 indicating extreme financial distress and no Altman Z-Score available, which raises significant bankruptcy risk. The company exhibits catastrophic profitability metrics, including a -9666.16% operating margin and -97.72% ROE, despite modest revenue growth of 31.5% YoY. The stock trades at a price/sales ratio of 40.31, far above peers, and is priced at $2.58—just above its 52-week low—despite a 5-year price decline of 100%. Analysts have only one target price of $23.00, suggesting limited conviction, and insider activity is neutral with no recent trades.
Key Strengths
31.5% year-over-year revenue growth indicates top-line expansion
High current and quick ratios (17.01 and 16.31) suggest strong short-term liquidity
Recent quarterly earnings surprise improved from -345.4% to -11.0%, showing some earnings stabilization
Insider sentiment is moderately positive at 60/100, indicating some internal confidence
Price is near 52-week low ($2.34), offering potential downside protection
Key Risks
Piotroski F-Score of 1/9 signals severe financial deterioration and high failure risk
Operating margin of -9666.16% and ROE of -97.72% reflect deep operational losses
No meaningful cash flow or free cash flow data, indicating inability to generate capital
Price/Sales of 40.31 is extremely high relative to peers and fundamentals
Analyst coverage is minimal (only 1 analyst), and target price is not reflective of current valuation
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
14
Weak
10
35
15
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 1/9, Catastrophic profitability metrics, No cash flow generation, Extremely high valuation multiples, 100% 5-year price decline
Confidence
95%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
- Price near 52-week low ($2.34)
Watchpoints
- Price/Sales of 40.31 is unsustainable
- No Graham Number or intrinsic value available
- No PEG or P/E to anchor valuation
- Trading at premium despite negative earnings
Future
35/100
Ref Growth rates
Positives
- 31.5% YoY revenue growth
- Improving earnings surprise trend (from -345% to -11%)
Watchpoints
- No forward P/E or earnings growth data
- Negative earnings trajectory despite revenue growth
- No free cash flow to support future growth
Past
15/100
Ref Historical trends
Positives
- Revenue growth has been consistent over 12 quarters
- Some improvement in earnings surprise in recent quarters
Watchpoints
- Consistently negative earnings with widening losses in early quarters
- 5-year price decline of 100%
- Historical EPS growth of +99.8% is misleading due to base effect from extreme losses
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- High current and quick ratios (17.01, 16.31) indicate strong liquidity
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial distress
- No Altman Z-Score available, but low score implies high bankruptcy risk
- Negative ROE and ROA indicate capital destruction
- No debt/equity or cash/debt data, but liquidity may be artificial
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- Negative earnings make dividend payment impossible
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.58
Analyst Target
$23.0
Upside/Downside
+791.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACON and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACON
Aclarion, Inc.
Primary
|
-100.0% | -100.0% | -98.0% | -64.7% | -38.3% | -6.2% |
|
AKAN
Akanda Corp.
Peer
|
-100.0% | -99.9% | -94.2% | -92.4% | -40.2% | +18.1% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
ADTX
Aditxt, Inc.
Peer
|
-100.0% | -100.0% | -100.0% | -99.5% | -15.5% | -5.2% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-0.19
PEG Ratio
N/A
P/B Ratio
0.12
P/S Ratio
40.31
EV/Revenue
-142.97
EV/EBITDA
1.45
Market Cap
$2.72M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-9666.16%
Gross Margin
-7.83%
ROE
-97.72%
ROA
-52.37%
Growth
Revenue and earnings growth rates
Revenue Growth
+31.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
17.01
Strong
Quick Ratio
16.31
Excellent
Cash/Share
$16.95
Quarterly Earnings History
EPS performance vs analyst estimates
2025-11-12
$-2.93
-11.0% surprise
2025-08-14
$-2.75
-21.6% surprise
2025-04-09
$-1628.09
-20.0% surprise
2024-11-14
$-1356.74
+16.7% surprise
Healthcare Sector Comparison
Comparing ACON against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Return on Equity (ROE)
-97.72%
This Stock
vs
-56.84%
Sector Avg
+71.9%
(Excellent)
Revenue Growth
31.5%
This Stock
vs
61.93%
Sector Avg
-49.1%
(Slower)
Current Ratio
17.01
This Stock
vs
3.47
Sector Avg
+390.9%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACON
Aclarion, Inc.
|
BEARISH | $2.72M | - | -97.7% | -% | $2.58 | |
|
AKAN
Akanda Corp.
|
BEARISH | $3.03M | 0.01 | -60.9% | -266.3% | $1.5 | |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | |
|
ADTX
Aditxt, Inc.
|
BEARISH | $1.1M | - | -% | -% | $0.62 | |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-26 | NESS BRENT | Chief Executive Officer | Purchase | 10 | $62 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
1 analysts
Ascendiant Capital
2025-11-20
Buy
Buy
Ascendiant Capital
2025-09-19
Buy
Buy
Past News Coverage
Recent headlines mentioning ACON from our newsroom.
Newest → oldest
No matching news yet.